For decades, tuberculosis (TB) has been one of the deadliest infectious diseases worldwide. Resistant strains of Mycobacterium tuberculosis are particularly problematic, as many established drugs are becoming increasingly ineffective against them. However, a research team from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Saarland University has now discovered a new family of natural substances that exhibit excellent activity against the TB pathogen. They have also investigated these substances so comprehensively that targeted further development is possible for the first time. The researchers have now published their findings in the journal Angewandte Chemie International Edition.

Two collaborative projects involving the Helmholtz Centre for Infection Research (HZI) are being funded with 100,000 euros each from the joint program "zukunft.niedersachsen" of the state of Lower Saxony and the Volkswagen Foundation. Both projects result from the collaboration between HZI and the MRC–University of Glasgow Centre for Virus Research (CVR), established in 2024 as part of a cooperation between the Helmholtz Association and the British Medical Research Council (MRC). The funded MARITH project will grow organoids from throat tonsil tissue to study the development of immunological memory in humans, while the ViReST project analyzes the sites of viral replication in respiratory infections and their impact on virus transmission.

The global skin care company Beiersdorf and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) have entered into a long-term, exclusive partnership. In this collaboration they aim to investigate the role of the skin microbiome in maintaining healthy skin. The goal is to identify natural products produced by microorganisms on the skin that have a positive effect on skin balance. The project is based on extensive data sets on microorganisms that inhabit human skin.